Trovax vaccine is designed to deliver a proprietary tumor associated antigen, 5T4, to a broad range of solid tumors. The vaccine is designed to use a pox virus vector, modified vaccinia virus Ankara (MVA).

In today’s deal, Sanofi-Aventis agrees to pay British biotech company Oxford BioMedica $690 million licensing fees for TroVax. Sanofi pays $39 million up front and $25 million installments. Sanofi will pay more if Trovax is approved to treat multiple cancers.
(full story…)

Clinical trials of Trovax vaccine include a small Phase II trial for prostate cancer, which began in Texas in 2006. This trial was designed for:

* Hormone-refractory prostate cancer
* TroVax administered either as a single agent or in combination with GM-CSF
* Recruitment was completed in July 2006
* To date 85% of patients treated with TroVax mounted an immune response

This Phase II trial in prostate cancer ran at the Methodist Hospital in Houston with Dr Robert Amato as principal investigator. The trial was designed to enroll 24 men with hormone-refractory prostate cancer who had previously received chemotherapy or had refused chemotherapy and had progressive disease. The trial was open label with two arms (12 patients each) to assess the activity of TroVax alone versus TroVax alongside an approved treatment for prostate cancer, granulocyte macrophage-colony stimulating factor (GM-CSF).
(full story…)

Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax For Cancer

PARIS, March 28, 2007 - Sanofi-aventis and Oxford BioMedica announced today that they have entered into an exclusive global license agreement to develop and commercialise TroVax® for the treatment and prevention of cancers.

TroVax® is Oxford BioMedica’s lead cancer immunotherapy. This therapeutic vaccine has been evaluated in clinical trials involving more than 180 patients with various forms of cancer. A Phase III trial - called TRIST - in renal cancer is ongoing.
(full story…)

Federal drug regulators on Tuesday released briefing documents that pose questions about the effectiveness of Provenge (sipuleucel-T), Seattle-based Dendreon Corp.’s experimental prostate cancer vaccine. On Thursday March 29 the Cell Tissue and Gene Therapy Committee (CTGT) will accept submissions from interested parties. The committee will then review the drug and recommend to the FDA that it be approved – or not be approved.

Prostate cancer advocates, acutely aware of the paucity of treatments available for men with hormone refractory prostate cancer, plan to attend the meeting to lobby for acceptance of Provenge.

The FDA committee’s questions pinpoint drug stability, efficacy and safety. A slightly higher rate of adverse events including explained and “unexplained” death (see below) occurred in men who took the vaccine.

FDA’s decision will be based on results of randomized trials, which tested Provenge against placebo (for which a dummy vaccination procedure was used). However, a subset of patients received Taxotere when their cancer progressed — either after Provenge, or after placebo or after placebo followed by a course of frozen-stored vaccine.
(full story…)